# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Josephine Baker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML049-SYN
- Date: 2026-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Colette Ashby-Nwosu, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: echocardiogram, cardiology consultation and breathlessness. **S**

## History of present illness

Ms. Baker returns two weeks after intake and is seen the same day by Dr. Mbeki-Fontaine of cardiology after her echocardiogram this morning. She is still breathless, but she describes it more exactly now: a sudden need to take a deep breath, often while sitting still or talking, as if she cannot get enough air, which began two or three days after she left the hospital. It does not build with effort the way it did on the day of the heart attack, and she has had no chest pressure, palpitations, ankle swelling, cough or waking at night breathless. She has taken every dose of aspirin, ticagrelor, atorvastatin, metoprolol and lisinopril, and has not needed nitroglycerin. Her home blood pressure averages 136/82. She has been to two cardiac rehabilitation sessions; on the treadmill she was not limited by breath. She is sleeping a little better. **S**

| Element | Detail |
|---|---|
| Breathlessness | Air hunger at rest and while talking, from two or three days after discharge; not exertional; no chest pain |
| Echocardiogram | Ejection fraction 52%; inferior hypokinesis; normal filling pressures |
| Home blood pressure | Average 136/82 mmHg |
| Rehabilitation | Two sessions completed without limiting breathlessness |
| Lipoprotein(a) | 172 nmol/L |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Episodes of air hunger at rest; no cough, wheeze or night breathlessness |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea or ankle swelling |
| Hematologic/lymphatic | Negative | No bleeding or unusual bruising |
| Psychiatric | Positive | Still worried about money and her children; sleeping a little better |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet daily **S**
- Lisinopril 10 mg oral tablet, one tablet daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/82 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 59.6 kg; BMI 21.1 kg/m². All vital signs are synthetic.

Lipoprotein(a): 172 nmol/L (high); LVEF by echocardiogram: 52%. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; talking in full sentences; blood pressure 136/82, pulse 62; oxygen saturation 98% on room air; weight 59.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; normal heart sounds; no murmur or gallop; right radial access site healed |
| Respiratory | Clear; no crackles or wheeze |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Breathlessness from ticagrelor** (T45.525A). Air hunger at rest beginning days after ticagrelor was started, with normal oxygen saturation, clear lungs, no anemia (hemoglobin 12.2 g/dL), an ejection fraction of 52% with normal filling pressures and no angina, fits the breathlessness that ticagrelor causes in a minority of patients; it is not dangerous, but it is distressing and threatens adherence. Dr. Mbeki-Fontaine agrees. Deconditioning after the hospital stay adds to it. **S**
   - Stop ticagrelor; start clopidogrel with a 600 mg loading dose 24 hours after the last ticagrelor dose, then 75 mg daily.
   - Continue aspirin 81 mg.
   - Dual antiplatelet therapy for twelve months from the heart attack; never stop without speaking to cardiology.
2. **Coronary artery disease after a non-ST-elevation myocardial infarction** (I25.10). No angina. Ejection fraction 52% with inferior hypokinesis from the infarct. Lipoprotein(a) 172 nmol/L, an inherited risk-enhancing level that strengthens the case for reaching the LDL goal. **S**
   - Continue atorvastatin 80 mg and metoprolol succinate 25 mg.
   - Lipid panel with the potassium check in one to two weeks, four to eight weeks after the statin start; ezetimibe if LDL is 70 mg/dL or higher.
   - Continue cardiac rehabilitation.
3. **High blood pressure** (I10). 136/82 in the clinic and at home, above the 130/80 target. **S**
   - Raise lisinopril to 10 mg daily.
   - Potassium and creatinine in one to two weeks.
4. **Financial strain** (Z59.86). Clopidogrel is a low-cost generic, which also helps. **S**
   - The social worker will see her at rehabilitation next week about debt advice.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, average of two readings; home readings) | Every visit | Completed today | 136/82 mmHg; home average 136/82; above target |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 59.6 kg, BMI 21.1; two rehabilitation sessions |
| Medication safety | Adherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitor | Every visit | Completed today | No missed doses; ticagrelor stopped for breathlessness and replaced by clopidogrel with a loading dose |
| Medication safety | Bleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated) | Every visit | Completed today | No bleeding; hemoglobin 12.2 g/dL at intake |
| Imaging | Echocardiogram for left ventricular function | After the infarction if not done or if function was reduced; then only with clinical change | Completed today | Ejection fraction 52%, inferior hypokinesis, normal filling pressures, no thrombus |
| Laboratory | Lipoprotein(a) | Once | Completed today | 172 nmol/L, a risk-enhancing level |
| Laboratory | Lipid panel | Four to eight weeks after a statin start or change, then every three to twelve months | Ordered | LDL 84 mg/dL at intake, only three weeks after atorvastatin 80 mg was started; panel ordered with the potassium check in one to two weeks |
| Laboratory | Metabolic panel (potassium, creatinine, eGFR) on an ACE inhibitor | One to two weeks after a start or dose change, then every six to twelve months | Ordered | Potassium 4.4, creatinine 0.82 mg/dL at intake; lisinopril raised today, panel due in one to two weeks |
| Laboratory | Hemoglobin A1c (no diabetes) | Yearly screening | Up to date | 5.6% at intake |
| Examination | ECG and troponin | Only with new or changing symptoms | Not indicated | No angina or change in symptoms suggesting ischemia; ECG at intake showed no acute change |
| Survey | Angina status (Seattle Angina Questionnaire-7) | At intake and every few months in the first year | Up to date | 70 at intake; next at the next visit |
| Survey | Depression screen (PHQ-2, then PHQ-9) | After the infarction and periodically | Up to date | PHQ-9 7 at intake with item 9 scored 0; repeat at about twelve weeks |
| Examination | Tobacco use | Every visit | Completed today | Never smoker |
| Referral | Cardiac rehabilitation | Within weeks of the infarction; 36 sessions | Completed today | Enrolled; two sessions completed |
| Self-management | Self-management: chest-pain action plan, nitroglycerin, women's warning symptoms | Every visit | Completed today | Action plan reviewed; nitroglycerin not needed |
| Medication safety | Medicine and visit costs | Every visit | Completed today | Clopidogrel is a low-cost generic; social worker next week |
| Referral | Cardiology consultation | After the infarction | Completed today | Seen by Dr. Mbeki-Fontaine today |

## Goal progress

- Twelve months of dual antiplatelet therapy from the heart attack without interruption. In progress; target 2027-03-24. **S**
- LDL cholesterol below 70 mg/dL with at least a 50% fall. In progress; target 2026-07-21. **S**
- Blood pressure below 130/80 mmHg. In progress; target 2026-05-26. **S**
- Complete cardiac rehabilitation and return to performing. In progress; target 2026-07-21. **S**
- Mood: PHQ-9 below 5 by twelve weeks. In progress; target 2026-07-21. **S**

## Medication changes

- Stopped: Ticagrelor 90 mg oral tablet, one tablet twice daily **S**
- Started: Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily **S**
- Stopped: Lisinopril 5 mg oral tablet, one tablet daily **S**
- Started: Lisinopril 10 mg oral tablet, one tablet daily **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association (Circulation 2025;151(13):e771-e862)
- Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016), American Heart Association (Circulation 2016;133(9):916-947)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026), Aether Forge

## Follow-up

- Metabolic panel in one to two weeks. Review in four weeks. Call for breathlessness that worsens, bleeding, or lightheadedness; call 911 for chest pain not relieved five minutes after one nitroglycerin. **S**
- Next scheduled visit 2026-05-26: four-week review after the change to clopidogrel: breathlessness, blood pressure, potassium and kidney function, and cardiac rehabilitation. **S**
